Li-Fraumeni Syndrome Study (LFS)

Precision Medicine for Individuals with Li-Fraumeni Syndrome

Nuances in cancer incidence, disease manifestation could inform clinical management of LFS.

Li-Fraumeni Syndrome (LFS) is an inherited disorder that leads to a higher risk of certain cancers, including sarcomas, brain tumors, breast cancer, and many others. It is inherited in an autosomal dominant manner and is often the result of heritable changes in the TP53 gene. The NCI has evaluated families with LFS since the syndrome was first recognized in 1969. DCEG is now expanding this research through a clinical study and participation in a multi-institutional collaboration.

The LFS study is open to patient enrollment. (LFS study protocol: 11-C-0255)

Li-Fraumeni Syndrome Study – Research Publications

For more information, contact Payal Khincha.